Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: A case report

Cardiovascular Ultrasound

Volumn 3, Issue , 2005, Pages

  Jochmann, Nicoline ^a   Kiecker, Felix ^a   Borges, Adrian C ^a   Hofmann, Maja A ^a   Eddicks, Stephan ^a   Sterry, Wolfram ^a   Baumann, Gert ^a   Trefzer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; VARDENAFIL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MELANOMA; PULMONARY HYPERTENSION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ADULT; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMIDAZOLES; INTERFERON-ALPHA; MELANOMA; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PURINES; SULFONES; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 24944447115     PISSN: 14767120     EISSN: 14767120     Source Type: Journal    
DOI: 10.1186/1476-7120-3-26     Document Type: Article

References (34)

1. Jonasch E, Haluska FG: Interferon in oncological practice: review of interferon biologic clinical applications, and toxicities. Oncologist 2001, 6:34-55.
2. Kirkwood J: Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002, 29:18-26.
3. Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH: Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003, 44:471-475.
4. Anderson P, Hoglund M, Rodjer S: Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. Am J Hematol 2003, 73:54-58.
5. Fruehauf S, Steider S, Topaly J, Ho AD: Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 2001, 80:308-310.
6. Kamisako T, Adachi Y, Chihara J, Yamamoto T: Interstitial pneumonitis and interferon-alpha. BMJ 1993, 306:896.
7. Kramers C, de Mulder PH, Barth JD, Wagener DJ: Acute right ventricular heart failure in a patient with renal cell carcinoma after interferon therapy. Neth J Med 1993, 42:65-68.
8. Nakamura F, Andoh A, Minamigushi H, Hodohara K, Fujiyama Y, Bamba TA: A case of interstitial pneumonitis associated with natural alpha-interferon therapy for myelofibrosis. Acta Haematol 1997, 97:222-224.
9. Kawano T, Shigehira M, Uto H, Nakama T, Kato J, Hayashi K, Maruyama T, Kuribayashi T, Chuman T, Futami T, Tsubouchi H: Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996, 91:309-313.
10. Sangster G, Kaye SB, Calman KC, Toy JL: Cutaneous vasculitis associated with interferon. Eur J Cancer Clin Oncol 1983, 19:1647-1649.
11. Nicod LP: Pulmonary hypertension. Swiss Med Wkly 2003, 1338:103-110.
12. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM: Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004, 43:25-32.
13. Politou M, Tsaftarides P, Vassiliades J, Siakantaris MP, Michail S, Nakopoulou L, Pangalis GA, Variopoulos G: Thrombotic microangiopathy in a patient with Sezary syndrome treated with interferon-alpha. Nephrol Dial Transplant 2004, 19:733-735.
14. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327:70-75.
15. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925-1932.
16. Mandegar M, Remillard CV, Yuan JX: Ion channels in pulmonary arterial hypertension. Prog Cardiovasc Dis 2002, 45:81-114.
17. Eddhaibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001, 108:1141-1150.
18. Hanaoka M, Kubo K, Hayano T, Koizumi T, Kobayashi T: Interferonalpha elevates pulmonary blood pressure in sheep - the role of thromboxane cascade. Eur J Pharmacol 1999, 370:145-151.
19. Dorfmuller P, Humbert M, Capron F, Muller KM: Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20:9-19.
20. Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli AM, Malorni W, Fais S, Belardelli F: Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001, 98:3022-3029.
21. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725-748.
22. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR: Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 1998, 158:279-288.
23. 3H)sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 2003, 63:1364-1372.
24. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:68-72.
25. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136:515-522.
26. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003, 108:2066-2069.
27. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD: Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003, 78:1207-1213.
28. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F: Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003, 42:158-164.
29. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F: Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003, 167:1139-1141.
30. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2003, 360:895-900.
31. Prasad S, Wilkinson J, Gatzoulis MA: Sildenafil in primary pulmonary hypertension. N Engl J Med 2000, 343:1342.
32. Ghofrani HA, for the Sildenafil 1140 Study Group: Efficiacy and safety of sildenafil citrate in pulmonary arterial hypertension: results of a multinational, randomized, double-blind, placebo-controlled trial. Am Coll Chest Phys 2004.
33. Corbin JD, Beasley A, Blount MA, Francis SH: Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochemistry International 2004, 45:859-863.
34. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004, 44:1488-1496.